QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND
Retrieved on:
Tuesday, December 7, 2021
Central nervous system, Microtubule, RNA splicing, Research, Population, Alzheimer's disease, Axon, Frontotemporal dementia, Temperature, Neurodegeneration, Motor neuron, Cell death, Drug discovery, Disease, Harvard University, Long-term impact of alcohol on the brain, View, Patient, Cell biology, Vance DeGeneres, Biomarker, Asos, Parkinson's disease, Golgi, Harvard Medical School, Amyotrophic lateral sclerosis, STMN2, Paralysis, CNS, Multimedia, The Human-Induced Earthquake Database, RNA, Symposium, Nature Neuroscience, Survival, Doctor of Philosophy, ALS, Golgi apparatus, Cell, Dementia, Vaccine, Pharmaceutical industry
CAMBRIDGE, Mass., Dec. 7, 2021 /PRNewswire/ -- QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced the presentation of preclinical findings from its STATHMIN-2 (STMN2) program, including novel biology linking TDP-43 loss to impaired Golgi trafficking through STMN2 function and rescue by QurAlis' antisense oligonucleotides (ASOs), as well as research to enable central nervous system (CNS) drug discovery in poster sessions at the 32nd International Symposium on ALS/MND being held virtually, December 7-10, 2021.
Key Points:
- Our research shows for the first time the connection between STMN2, TDP-43, and important cell biology of ALS.
- Dr. Hinckley stated, "One of the challenges in the research of neurodegenerative diseases, such as ALS, is the availability of neuronal cells.
- Our approach is incredibly enabling from a drug discovery perspective to help neuronal research move more rapidly."
- QurAlis' proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations.